BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. This paper was submitted to a another journal from BMJ but declined for publication following peer review. The authors addressed the reviewers' comments and submitted the revised paper to BMJ Open. The paper was subsequently accepted for publication at BMJ Open.
(1) The authors indicate that eligible trial reports are trials to treat major depressive disorder (MDD) defined based on the DSM. They should also include treatment for major depression as assessed using ICD. Additionally, they should explicitly define requirements for this to be a valid diagnosis. Will they require a validated diagnosis interview? Only clinician diagnosis? This should be clarified.
(2) The authors indicate that they will include pilot and feasibility studies. Outcomes for these are often process-related (e.g., resource requirements, acceptability of interventions). Are they planning on including these outcomes? Or do they need to specify that they are including only outcomes related to health status? This should be clarified.
(3) Ideally the database search strategy would be peer-reviewed, and PRESS is an option for this. If this is not done, it should be noted as a limitation.
(4) The authors should indicate where they are in the process of conducting the review and provide dates (either past if started or anticipated if not).
(5) In the PICOT, the "T" is intended for the timing of outcome assessments in the course of an included trial. It is not intended for when trials were published as used in the protocol. The authors should clarify the timing of outcomes in each trial that they will include. The publication dates of eligible trials should be listed separately in the inclusion/exclusion section.
(6) It is common in title/abstract review that if either reviewer deems a citation potentially eligible for inclusion, the citation moves to full-text review without arbitration at the title and abstract stage. The authors are encouraged to consider using this model as reviewers at the title/abstract level don't have full information and if either reviewer believes the citation might be eligible, there is good reason to review the full text.
REVIEWER
Peng Xie Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China REVIEW RETURNED 15-Jul-2018
GENERAL COMMENTS
This is a scoping review protocol that focused on outcome reporting heterogeneity in randomized controlled trials of MDD treatments in adolescents. This is an interesting and meaningful topic. However the current form of this paper is so brief and vague that I do not understand why it needs to be published.
Major Comments: 1. Why the authors only included studies for MDD in adolescents?
In my previous studies, I found that many RCTs concurrently included children (6-12y) and adolescents (13-18y).
2. I think the author should generally review the current trial outcomes measurement, including the number, range, and reliability.ect.
3. The rational of core outcomes sets (COS), and how to complete and develop it, should be fully described.
4. A large numbers of studies used K-SADS or ICD as diagnostic criteria for adolescents MDD. How the authors deal with these studies?
5. I think embase and web of science are also important databases that should be considered to search. In addition, it is better to search some trial registers websites, such as clinicaltrials.gov and the International Clinical Trials Registry Platform (ICTRP) in the WHO.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Brett Thombs Institution and Country: McGill University and Jewish General Hospital Canada Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below The protocol describes the methods that will be used to conduct a scoping review on outcomes used in treatment trials for adolescent depression. This is an important topic and there is a high likelihood that the proposed research will generate valuable results that lead to an increased rigor in trials research in the field. The protocol is clearly written and well-justified. Comments address areas where clarification would be useful.
We have now specified that trial eligibility includes those where diagnoses were made using ICD criteria, as well as DSM criteria, using a validated diagnostic interview and/or a clinical diagnosis based on these criteria (see "Population" under "Eligibility criteria" in the Methods and Analysis section).
We (3) Ideally the database search strategy would be peer-reviewed, and PRESS is an option for this. If this is not done, it should be noted as a limitation.
We have now provided additional information on the development process of the database search strategy, including review of the search using PRESS (see "Information sources and search strategy" in the Methods and Analysis section).
The review dates and the review progress to date have been added (see "Protocol" in the Methods and Analysis section).
For simplicity, the "T" in the PICOT has been removed as there are no relevant timing restrictions to be described. We have clarified in the text that there will be no restrictions on when the outcomes were measured or duration of follow-up after initiation of the intervention as are interested in the diversity of timing of outcomes in RCTs (see last paragraph under "Eligibility criteria" in the Methods and Analysis section). As suggested, the publication dates of eligible trials are now described elsewhere (see last paragraph under "Eligibility criteria" in the Methods and Analysis section).
(6) It is common in title/abstract review that if either reviewer deems a citation potentially eligible for inclusion, the citation moves to full-text review without arbitration at the title and abstract stage. The authors are encouraged to consider using this model as reviewers at the title/abstract level don't have full information and if either reviewer believes the citation might be eligible, there is good reason to review the full text. Lillie E, et al., BMJ Open 2017; 7:e013474; Glonti K, Cauchi D, Cobo E, et al. BMJ Open 2017; 7:e017468 
